Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study (Q34471919)

2 August 2017

Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study (English)

1 reference

2 August 2017

3

Patricia L Blount

1 reference

2 August 2017

5

Robert D Odze

1 reference

2 August 2017

6

Carissa A Sanchez

1 reference

2 August 2017

Thomas L Vaughan

1

1 reference

2 August 2017

Linda M Dong

2

1 reference

2 August 2017

Kamran Ayub

4

1 reference

2 August 2017

Peter S Rabinovitch

7

1 reference

2 August 2017

Brian J Reid

8

1 reference

2 August 2017

language of work or name

1 reference

1 December 2005

1 reference

Lancet Oncology Commission

2 August 2017

1 reference

2 August 2017

6

1 reference

2 August 2017

945-952

1 reference

2 August 2017

12

1 reference

Demographic variations in the rising incidence of esophageal adenocarcinoma in white males

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Population attributable risks of esophageal and gastric cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Barrett's esophagus: update on screening, surveillance, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Are screening and surveillance for Barrett's oesophagus really worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Barrett's esophagus: development of dysplasia and adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Adenocarcinoma arising in Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

A prospective study of aspirin use and the risk for colorectal adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Aspirin use and cancers of the upper aerodigestive tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

NSAIDs and esophageal cancer: ready for trials but not yet broad clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Analysis of aspirin-associated risks in healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Prevention of colorectal cancer through the use of COX-2 selective inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Cyclooxygenase-2 expression in Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970431-9

7 January 2021

10.1016/S1470-2045(05)70431-9

Identifiers

DOI

1 reference

2 August 2017

1 reference